Dr. Shivashankara Swamy M S

MBBS, MD MEDICINE (GOLD MEDALIST), MRCP, DNB (MEDICAL ONCOLOGY), ECMO

Consultant Medical Oncology

Book an Appointment

Rajiv Gandhi Cancer Institute, Sector - 5, Rohini, Delhi - 110 085

About

Consultant, Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Center, From June 2020. I have experience in the management of cancer patients from diagnosis to treatment and palliative care. It involves utilizing appropriate diagnostic tests such as tumor markers, immunohistochemistry, and molecular studies for an accurate diagnosis. Treatment involves administration of chemotherapy, targeted therapy, metronomic therapy, and Immunotherapy. Also experienced in Stem cell transplant and cellular therapies.

Specialized Areas

Molecular Oncology
Personalized medicine
Immuno-oncology

Educational Background

MBBS from BMCRI (Bangalore Medical College and Research Institute) Karnataka (July 2005 to March 2011)
MD (Medicine) from PGIMER, RML Hospital, New Delhi. (June 2012 to May 2015)
MRCP part 1 & 2 (UK), 2021
DNB Medical Oncology from Army Hospital Research and Referral, Delhi (April 2017 to March 2020)
ECMO (European Certified Medical Oncologist)

Experience

Journal reviewer training at Indian Journal of Medical and Pediatric oncology from Jan 2020 to December 2020
Reviewer course at Publons
Virtual Mentorship Programme at ASCO from October 2020
Clinical Trialist course for young oncologists
Assistant Professor of Medicine, AIMS, Bellur Karnataka. From September 2016 to February 2017
Senior Resident- Department of Medicine – RML Hospital from July 2015 to January 2016.
Junior Resident – RML Hospital from June 2012 to May 2015

Professional Journey

Achievements

Talk on “Ideal first-line strategy in EGFR mutated metastatic Lung Cancer” at Lung Cancer Update, Delhi chapter, October 2020
Paper presentation on “Outcomes and prognostic factors in localized soft tissue sarcoma: Prospective observational study” at ESMO Congress September 2020
Oral Presentation “cyclophosphamide followed by intravenous busulfan (CY-BU) As myeloablative conditioning: impact on veno-occlusive disease (VOD) and Transplant outcomes, a single centre experience” at EBMT Highlights APAC 2018, India.
Best of SABCS, India chapter 2020 at Mumbai, India
Indian Myeloma Congress, 2020 at Hyderabad, India
Best of SABCS, India Chapter 2019 at Delhi, India
Indian Myeloma Congress, 2018 at Delhi, India

Awards

Gold medalist for being a university topper in MD medicine.
First Prize in case Presentation at C4 – Challenging Case Capsules in Cancer, 2019 organized Max Institute of Cancer Care New Delhi
First Prize in Adrenaline Rush Quiz 2019 organized by Max Institute of Cancer Care New Delhi
2nd Prize in Best of SABCS Delhi chapter quiz

Publication

Outcomes and prognostic factors in localized soft tissue sarcoma: Prospective observational study, September 2020, Annals of Oncology 31:S989. DOI:10.1016/j.annonc.2020.08.1888
Real-world experience of treatment and outcome in ALK-rearranged metastatic non-small cell lung cancer: A multicenter study from India. Current problems in cancer.2020 www.sciencedirect.com
Fulvestrant: Do not forget the history and opportunities for cost-saving from real-world data. Cancer Res Stat Treat 2020;3:663 (PDF) CancerResStatTreat33663-6164147-17072. https://www.researchgate.net/publication/344361031_CancerResStatTreat33663-6164147-170721_1
Correlations of Programmed death-ligand 1Expression with gene Expression and Clinicopathological parameters in Indian patients with non-small cell Lung cancer.www.lungindia.com
Genomic architecture of gallbladder cancer: Results of a first prospective study, May 2020, Journal of Clinical Oncology 38(15_suppl):e16628-e16628, 2020 DOI:10.1200/JCO.2020.38.15_suppl.e16628
Pharmacogenomics, January 2020, Indian journal of medical and pediatric oncology 41(4):550. DOI:10.4103/ijmpo.ijmpo_61_20

Membership

American society of Clinical Oncology
European society of Medical oncology

Dr. Shivashankara Swamy M S